I think that's exactly [Technical difficulty—Editor]. In my opening remarks, I referenced the role of the TRIPS waiver campaign in helping create some of that momentum and increasing pressure. I also think a policy of non-retaliation around use or indication of existing TRIPS flexibilities would be very helpful in this space, because it would allow countries the space to drive their own negotiations with pharmaceutical companies within existing legal boundaries and our existing IP framework. I think that's a way of driving this forward that addresses some of the concerns of industry about unpredictability and the idea of changing the rules of the game midway. These are the rules of the game, so it's not changing them. It's using the rules as they're written.
The one thing I would just respond to in your specific comments is around tiered pricing. We do need to be on the lookout for changes to pricing that pharmaceutical companies might want to put in place later on, after they perceive that public pressure around the immediate pandemic has receded. However, tiered pricing is not always a bad thing. It's often quite a useful way of getting access to low- and middle-income countries and getting universal access to prices that are affordable to different countries, understanding that different countries have different capacities to pay for medicines, even if they're respecting IP and even if they want to contribute to the overall innovation ecosystem.
Therefore, I don't think tiered pricing is necessarily bad, so long as the prices are affordable in every setting in which they are offered.